Retinoblastoma Clinical Trials 2023

Retinoblastoma Clinical Trials 2023

Retinoblastoma research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in retinoblastoma clinical trials today.

Popular filter options for retinoblastoma trials

Retinoblastoma Clinical Trials With No Placebo

View 14 retinoblastoma medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to retinoblastoma

What are the top hospitals conducting retinoblastoma research?

When it comes to fighting retinoblastoma, a rare and aggressive eye cancer that primarily affects children, several leading hospitals are conducting groundbreaking clinical trials. St. Jude Children's Research Hospital in Memphis leads the charge with four active retinoblastoma trials and an impressive total of ten trials dedicated to this condition since their first recorded trial in 1997. Meanwhile, on the West Coast, Children's Hospital Los Angeles is making significant strides with three ongoing retinoblastoma trials and a history of eleven completed studies since their inaugural trial in 2000.

In Saint Louis, Washingtone cancer that primarily affects children, several leading hospitals are conducting groundbreaking clinical trials. St. Jude Children's Research Hospital in Memphis leads the charge with four active retinoblastoma trials and an impressive total of ten trials dedicated to this condition since their first recorded trial in 1997. Meanwhile, on the West Coast, Children's Hospital Los Angeles is making significant strides with three ongoing retinoblastoma trials and a history of eleven completed studies since their inaugural trial in 2000.

In Saint Louis, Washington University School of Medicine is contributing to the advancement of treatment options for retinoblastoma through its three active clinical trials. Since initiating their first recorded trial in 2005, they have conducted six studies aimed at improving outcomes for patients diagnosed with this challenging condition. Similarly, Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center in Houston is actively engaging in three current retinoblastoma trials while having completed four previous investigations since recording their initial trial also in 2005.

Duke University Medical Center located in Durham completes this group by offering hope through its involvement in cutting-edge research on retinoblastoma. With three active clinical trials underway and seven all-time completed studies dating back to their entry into the field of study also starting from the year 2005.The efforts undertaken by these remarkable institutions reflect not only dedication but also highlight our collective commitment towards finding effective treatments for children battling against this unforgiving disease.

The collaboration among these top hospitals serves as a beacon of optimism for both patients and researchers alike as we strive toward eradicating retinoblastoma once and for all. Each step taken brings us closer to breakthroughs that hold promise for brighter futures not only for affected families but ultimately lead us towards conquering childhood cancers globally

Which are the best cities for retinoblastoma clinical trials?

When it comes to retinoblastoma clinical trials, several cities have emerged as key players in advancing research and treatment options. Houston, Texas leads the way with 6 active trials focusing on treatments like CVE, melphalan, and filgrastim. Memphis, Tennessee closely follows with 5 ongoing studies investigating CRADLE, topotecan, and Stratum A interventions. Saint Louis, Missouri and San Francisco, California, Tennessee closely follows with 5 ongoing studies investigating CRADLE, topotecan, and Stratum A interventions. Saint Louis, Missouri and San Francisco, California both contribute to the progress of retinoblastoma clinical trials with their respective 4 active studies exploring various approaches including melphalan and filgrastim. Lastly, Las Vegas, Nevada also plays a significant role with 4 ongoing trials primarily examining the potential benefits of filgrastim. These cities collectively provide opportunities for patients battling retinoblastoma to participate in cutting-edge clinical trials that could potentially revolutionize treatment outcomes for this condition.

Which are the top treatments for retinoblastoma being explored in clinical trials?

In the realm of retinoblastoma, clinical trials are paving the way for innovative treatments. Leading the charge is melphalan, currently under investigation in two active trials and boasting a total of ten all-time retinoblastoma trials since its introduction in 2009. Another promising contender is the second-generation 4-1BBζ B7H3-EGFRt-DHFR treatment, with one ongoing trial and first listed in 2020. Additionally, topotecan episcleral plaque and episcleral topotecan have each entered the scene with one active trial and one all-time retinoblastoma trial since their respective introductions in 2020 and 2021. Rounding out this list of potential breakthroughs is the second-generation 4-1BBζ EGFR806-EGFRt treatment—currently being explored in one active trial after its first listing in 2019. These medical advancements bring renewed hope to those affected by retinoblastoma as researchers continue to push boundaries towards finding effective solutions.

What are the most recent clinical trials for retinoblastoma?

Exciting developments in retinoblastoma research have led to recent clinical trials that offer new hope for patients. One such trial involves the use of palbociclib with TAS-116, which is currently in Phase 1. This combination therapy has shown promise and could potentially improve treatment outcomes for retinoblastoma. Another trial focuses on a treatment regimen utilizing CVE and melphalan, also known as cyclophosphamide-vincristine-etoposide combined with melphalan, which is now in Phase 2. This approach aims to enhance the effectiveness of current treatments for retinoblastoma through careful drug combinations. Additionally, episcleral topotecan is being investigated as a potential therapeutic option for this eye cancer during its early stages (Phase 1). With these ongoing studies exploring innovative approaches, there's renewed optimism for improving outcomes and quality of life for individuals affected by retinoblastoma

What retinoblastoma clinical trials were recently completed?

Recently completed clinical trials for retinoblastoma, a rare form of eye cancer primarily affecting children, have shown promising results in advancing treatment options. These trials included investigations into new therapeutic approaches and innovative medications. Notably, the trial conducted by St. Jude Children's Research Hospital evaluated the efficacy of intravitreal melphalan as a localized chemotherapy option for retinoblastoma patients. Additionally, Memorial Sloan Kettering Cancer Center spearheaded a trial focusing on targeted molecular therapies to better understand and combat this challenging disease. The completion of these trials signifies significant progress in the field and offers hope for improved outcomes for children with retinoblastoma.